AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine analysts that ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a report issued on Monday, MarketBeat reports. They presently have a GBX 140 ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

AstraZeneca Pharma India (APIL ... Health Government of India for the additional indication of Olaparib film coated Tablets 100mg and 150 mg (Lynparza). Nippon India Small Cap Fund (G) 431.97 6,58,075 ...

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...